1. Introduction
===============

Endometriosis is a very common condition for women at reproductive age.^\[[@R1]--[@R3]\]^ It has been reported that about 6% to 10% women experience such condition.^\[[@R4],[@R5]\]^ It mainly manifests as the dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia, especially as the endometriosis-associated pain (EAP).^\[[@R6]--[@R9]\]^ It can result in frequent chronic pain and even infertility, if such condition cannot be treated very well.^\[[@R10]--[@R13]\]^ Many factors may lead to this issue, including retrograde menstruation, genetic, environment, and immune factors.^\[[@R14],[@R15]\]^

Several treatment strategies are utilized to treat such condition, including oral contraceptives,^\[[@R16],[@R17]\]^ progestin montherapy,^\[[@R18],[@R19]\]^ danazol,^\[[@R20]\]^ and gonadotropin-releasing hormone.^\[[@R21]\]^ However, all those therapies are still inadequate, and often result in lots of adverse events. Thus, efficacious and safe treatments for long-term intervention for such condition are still needed.

It has been reported that complementary and alternative medicine can treat EAP, such as Chinese acupuncture, moxibustion, yoga, psychotherapy, and neuromuscular electrical stimulation (NMES),^\[[@R22]--[@R28]\]^ especially for NMES. However, limited data of NMES for the treatment of EAP have been reported presently. In this study, we retrospectively analyzed the effect and safety of NMES in patients with EAP.

2. Methods
==========

This retrospective study was approved by the Medical Ethical Committee of The People\'s Hospital of Yan'an. All patients had provided the written informed consent.

2.1. Design
-----------

This retrospective study was conducted at The People\'s Hospital of Yan'an between January 2014 and December 2016. It included 154 female patients with EAP. All those subjects were divided into a treatment group and a control group according to the different interventions they received. Of those, 83 patients underwent NMES and were assigned to a treatment group, while other 71 patients were at waiting list and were assigned to a control group.

2.2. Patients
-------------

In this study, 154 eligible female patients aged from 18 to 42 years with confirmed diagnosis of EAP by a history of histological confirmed endometriosis and chronic pelvic pain were included. Patients were excluded if they were pregnancy, drug or alcohol addiction, and received medication and NMES or electroacupuncture within 1 month before this study.

2.3. Treatments
---------------

All 83 patients in the treatment group received NMES by using the NMES device (HANS-100; Nanjing Jisheng Medical Technology Co., Ltd, Nanjing, Jiangsu Province, China). It applied 2 gel pads attached to bilateral acupoints of Sanyinjiao (SP 6) (3 *cun* directly above the tip of the medial malleoulus on the posterior border of the tibia), Zhongji (CV 3) (on the anterior median line of the lower abdomen, 4 *cun* below the belly button), and Guanyuan (CV 4) (on the anterior median line of the lower abdomen, 3 *cun* below the belly button) with 2 to 100 Hz for 30 minutes each session, once daily, 3 sessions weekly for a total of 10 weeks. The 71 patients in the control group were at waiting list and received no NMES therapy.

2.4. Outcome measurements
-------------------------

The primary outcome was pain, measured by the numerical rating scale (NRS),^\[[@R29]\]^ and the Endometriosis Symptom Severity score (ESSS).^\[[@R30]\]^ NRS ranges from 0 to 10, with higher score indicating more pain.^\[[@R29]\]^ ESSS tool required subjects to rate dysmenorrhea, dyspareunia, and nonmenstrual pain with 4 different types, including absent, mild, moderate, and severe. It varies from 0 to 9, with higher score indicating severer symptoms.^\[[@R30]\]^

The secondary outcome of quality of life was measured by the 36-Item Short Form Health Survey (SF-36).^\[[@R31]\]^ It included 2 main subscales of Physical Component Summary (PCS) and Mental Component summary (MCS). It ranges from 0 to 100, with higher score indicating less disability.^\[[@R31]\]^ All outcomes were measured before and after 5-week, and 10-week treatment. Moreover, all adverse events occurred in this study were documented.

2.5. Statistical analysis
-------------------------

All data were analyzed by using SPSS software (SPSS Version 19.0; IBM Corp., Armonk, NY). Continuous data were analyzed by the *t* test or Mann--Whitney rank sum test. Categorical data were analyzed by the Pearson Chi-square test or Fisher exact test. *P* \< .05 was regarded as the statistical significance between the 2 groups.

3. Results
==========

Patients' characteristics of both groups at baseline are listed in Table [1](#T1){ref-type="table"}. There are not significant differences in all characteristics between the 2 groups. These characteristics include age, race, weight, body mass index, and pain duration, stage of endometriosis, and patients with infertility, NRS, ESSS, SF-36, and previous analgesic medication used (Table [1](#T1){ref-type="table"}).

###### 

Patients' characteristics of both groups.
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After 5-week treatment, there are no significant differences in pain, measured by NRS (*P* = .14, Table [2](#T2){ref-type="table"}), and ESSS (*P* = .12, Table [2](#T2){ref-type="table"}), and quality of life, measured by SF-36 (PCS, *P* = .18; MCS, *P* = .21; Table [3](#T3){ref-type="table"}) between the 2 groups.

###### 

Primary outcome measurements after 5-week and 10-week treatment (Change from before treatment).
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###### 

Secondary outcome measurements after 5-week and 10-week treatment (change from before treatment).
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After 10-week treatment, patients in the treatment group showed better effectiveness in NRS (*P* = .02, Table [2](#T2){ref-type="table"}), ESSS (*P* = .04, Table [2](#T2){ref-type="table"}), and SF-36 (PCS, *P* \< .01; MCS, *P* \< .01; Table [3](#T3){ref-type="table"}), than the patients in the control group.

Adverse events are summarized in Table [4](#T4){ref-type="table"}. No significant differences of all adverse events were found between 2 groups. Mild and acceptable adverse events occurred, and no severe adverse events were recorded in both groups.

###### 

Adverse events between 2 groups.
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4. Discussion
=============

Presently, no study has specifically focused on investigating the efficacy and safety of NMES for the treatment of Chinese female patients with EAP. Previous related study explored the effect of psychotherapy-combined somatosensory stimulation for relieving EAP and improving quality of life in patients with EAP.^\[[@R28]\]^ Its results demonstrated that such therapy can either reduce global and pelvic pain, and dyschezia, or enhance quality of life in patients with endometriosis. After 6-month and 24-month treatment, all achieved stable improvements.^\[[@R28]\]^

This study is the clinical study to specifically explore the effect and safety of NMES for treating Chinese patients with EAP. In this study, we utilized NMES for treating patients with EAP, compared with such kind of patients at waiting list. The results of this study did not find promising effect of NMES for EAP, assessed by the scales of NRS, ESSS, PCS, and MCS after 5-week treatment. However, NMES exerts encouraging effect in either pain relief, measured by NMES and ESSS, or quality of life improvement, measured by SF-36 (PCS and MCS) after 10-week treatment. In addition, only minor and acceptable adverse events occurred in this study.

Several limitations existed in this retrospective study. First, this study did not include placebo control group, because all data of this study were just based on the current available completed cases. Thus, this study only evaluates the effect, but not the efficacy of NMES for the treatment of EAP. Then, this study did not further assess the effect of NMES after 10-week treatment in longer term. Therefore, follow-up effectiveness evaluation should also be considered in the future study.

5. Conclusion
=============

The results of this study showed that NMES is effective in female Chinese patients with EAP after 10-week treatment. Further studies are still needed to warrant this result.
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